[Intravitreal chemotherapy for intraocular lymphoma]

Publication

[Intravitreal chemotherapy for intraocular lymphoma]

Journal Paper/Review - Feb 1, 2003

Helbig H, Cerny Thomas, de Smet M D

Citation

Helbig H, Cerny T, de Smet M. [Intravitreal chemotherapy for intraocular lymphoma]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2003; 100:145-9.

Type

Journal Paper/Review (Deutsch)

Journal

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2003; 100

Publication Date

Feb 1, 2003

Issn Print

0941-293X

Pages

145-9

Brief description/objective

Primary CNS and intraocular non-Hodgkin's lymphoma is currently mostly treated with systemic chemotherapy. After initially successful tumor regression, recurrence is common and usually treated with radiotherapy. However, after good primary therapeutic response, new tumor growth is frequently observed. Because of actinic complications, radiotherapy can be applied only once. For an intraocular recurrence of primary CNS and intraocular lymphoma, intravitreal chemotherapy (0.4 mg methotrexate and 0.4 mg dexamethasone weekly for 4 weeks and once a month thereafter) can be performed. A few weeks after initiation, regression of intraocular tumors and eventually improvement of vision can be achieved. Eyes remained free of recurrence up to 2 years after initiation of intravitreal injections. Intravitreal chemotherapy is an effective treatment for ocular recurrence of primary CNS and intraocular lymphoma after systemic chemotherapy and radiotherapy.